The ALT pathway generates telomere fusions that can be detected in the blood of cancer patients.

Muyas F, Rodriguez MJG, Cascão R, Afonso A, Sauer CM, Faria CC, Cortés-Ciriano I, Flores I.

Nat Commun, 2024

doi:10.1038/s41467-023-44287-8.

Molecular landscape and functional characterization of centrosome amplification in ovarian cancer.

Sauer CM, Hall JA, Couturier DL, Bradley T, Piskorz AM, Griffiths J, Sawle A, Eldridge MD, Smith P, Hosking K, Reinius MAV, Morrill Gavarró L, Mes-Masson AM, Ennis D, Millan D, Hoyle A, McNeish IA, Jimenez-Linan M, Martins FC, Tischer J, Vias M, Brenton JD.

Nat Commun, 2023

doi:10.1038/s41467-023-41840-3.

Author Correction: The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma.

Smith P, Bradley T, Gavarró LM, Goranova T, Ennis DP, Mirza HB, De Silva D, Piskorz AM, Sauer CM, Al-Khalidi S, Funingana IG, Reinius MAV, Giannone G, Lewsley LA, Stobo J, McQueen J, Bryson G, Eldridge M, BriTROC Investigators, Macintyre G, Markowetz F, Brenton JD, McNeish IA.

Nat Commun, 2023

doi:10.1038/s41467-023-41611-0.

The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma.

Smith P, Bradley T, Gavarró LM, Goranova T, Ennis DP, Mirza HB, De Silva D, Piskorz AM, Sauer CM, Al-Khalidi S, Funingana IG, Reinius MAV, Giannone G, Lewsley LA, Stobo J, McQueen J, Bryson G, Eldridge M, BriTROC Investigators, Macintyre G, Markowetz F, Brenton JD, McNeish IA.

Nat Commun, 2023

doi:10.1038/s41467-023-39867-7.

De novo detection of somatic mutations in high-throughput single-cell profiling data sets.

Muyas F, Sauer CM, Valle-Inclán JE, Li R, Rahbari R, Mitchell TJ, Hormoz S, Cortés-Ciriano I.

Nat Biotechnol, 2023

doi:10.1038/s41587-023-01863-z.

High-grade serous ovarian carcinoma organoids as models of chromosomal instability.

Vias M, Morrill Gavarró L, Sauer CM, Sanders DA, Piskorz AM, Couturier DL, Ballereau S, Hernando B, Schneider MP, Hall J, Correia-Martins F, Markowetz F, Macintyre G, Brenton JD.

Elife, 2023

doi:10.7554/elife.83867.

The genomic landscape of recurrent ovarian high grade serous carcinoma: the BriTROC-1 study

Smith P, Bradley T, Gavarró LM, Goranova T, Ennis D, Mirza H, De Silva D, Piskorz A, Al-Khalidi S, Sauer C, Funingana I, Reinius M, Giannone G, Lewsley L, Stobo J, McQueen J, Bryson G, Eldridge M, Macintyre G, Markowetz F, Brenton J, McNeish I, The BriTROC Investigators.

2022

doi:10.1101/2022.10.21.22280992.

Clonal somatic copy number altered driver events inform drug sensitivity in high-grade serous ovarian cancer.

Martins FC, Couturier DL, de Santiago I, Sauer CM, Vias M, Angelova M, Sanders D, Piskorz A, Hall J, Hosking K, Amirthanayagam A, Cosulich S, Carnevalli L, Davies B, Watkins TBK, Funingana IG, Bolton H, Haldar K, Latimer J, Baldwin P, Crawford R, Eldridge M, Basu B, Jimenez-Linan M, Mcpherson AW, McGranahan N, Litchfield K, Shah SP, McNeish I, Caldas C, Evan G, Swanton C, Brenton JD.

Nat Commun, 2022

doi:10.1038/s41467-022-33870-0.

Molecular landscape and functional characterization of centrosome amplification in ovarian cancer

Sauer CM, Hall JA, Couturier D, Bradley T, Piskorz AM, Griffiths J, Sawle A, Eldridge MD, Smith P, Hosking K, Reinius MA, Gavarró LM, Mes-Masson A, Ennis D, Millan D, Hoyle A, McNeish IA, Jimenez-Linan M, Martins FC, Tischer J, Vias M, Brenton JD.

2022

doi:10.1101/2022.09.13.507750.

LGR5 targeting molecules as therapeutic agents for multiple cancer types

Chen H, Mueller N, Stott K, Rivers E, Kapeni C, Sauer CM, Beke F, Walsh S, Ashman N, O’Brien L, Fard AR, Godsinia A, Joud F, Giger O, Zlobec I, Olan I, Aitken SJ, Hoare M, Mair R, Serrao E, Brenton JD, Garcia-Gimenez A, Richardson SE, Huntly B, Spring DR, Skjødt M, Skjødt K, de la Roche M, de la Roche M.

2022

doi:10.1101/2022.09.01.506182.

High-grade serous ovarian carcinoma organoids as models of chromosomal instability

Vias M, Morrill Gavarró L, Sauer CM, Sanders D, Piskorz AM, Couturier D, Ballereau S, Hernando B, Hall J, Correia-Martins F, Markowetz F, Macintyre G, Brenton JD.

2022

doi:10.1101/2022.09.01.506155.

Longitudinal monitoring of disease burden and response using ctDNA from dried blood spots in xenograft models.

Sauer CM, Heider K, Belic J, Boyle SE, Hall JA, Couturier DL, An A, Vijayaraghavan A, Reinius MA, Hosking K, Vias M, Rosenfeld N, Brenton JD.

EMBO Mol Med, 2022

doi:10.15252/emmm.202215729.

Longitudinal monitoring of disease burden and response using ctDNA from dried blood spots in xenograft models

Sauer CM, Heider K, Belic J, Boyle SE, Hall JA, Couturier D, An A, Vijayaraghavan A, Reinius MA, Hosking K, Vias M, Rosenfeld N, Brenton JD.

2022

doi:10.1101/2022.01.15.476442.

Absolute copy number fitting from shallow whole genome sequencing data

Sauer CM, Eldridge MD, Vias M, Hall JA, Boyle S, Macintyre G, Bradley T, Markowetz F, Brenton JD.

2021

doi:10.1101/2021.07.19.452658.

Somatic chromosomal number alterations affecting driver genes inform <i>in-vitro</i> and clinical drug response in high-grade serous ovarian cancer

Martins FC, Couturier D, Santiago Id, Sauer CM, Vias M, Angelova M, Sanders D, Piskorz A, Hall J, Hosking K, Amirthanayagam A, Cosulich S, Carnevalli L, Davies B, Watkins TBK, Funingana G, Bolton H, Haldar K, Latimer J, Baldwin P, Crawford R, Eldridge M, Basu B, Jimenez-Linan M, McGranahan N, Litchfield K, Shah SP, McNeish I, Caldas C, Evan G, Swanton C, Brenton JD.

2020

doi:10.1101/2020.10.04.325365.

Hypoxia regulates GR function through multiple mechanisms involving microRNAs 103 and 107.

Yang N, Berry A, Sauer C, Baxter M, Donaldson IJ, Forbes K, Donn R, Matthews L, Ray D.

Mol Cell Endocrinol, 2020

doi:10.1016/j.mce.2020.111007.

Development and validation of a universal blood donor genotyping platform: a multinational prospective study.

Gleadall NS, Veldhuisen B, Gollub J, Butterworth AS, Ord J, Penkett CJ, Timmer TC, Sauer CM, van der Bolt N, Brown C, Brugger K, Dilthey AT, Duarte D, Grimsley S, van den Hurk K, Jongerius JM, Luken J, Megy K, Miflin G, Nelson CS, Prinsze FJ, Sambrook J, Simeoni I, Sweeting M, Thornton N, Trompeter S, Tuna S, Varma R, Walker MR, NIHR BioResource, Danesh J, Roberts DJ, Ouwehand WH, Stirrups KE, Rendon A, Westhoff CM, Di Angelantonio E, van der Schoot CE, Astle WJ, Watkins NA, Lane WJ.

Blood Adv, 2020

doi:10.1182/bloodadvances.2020001894.